AR123327A1 - Formulaciones de un inhibidor de mcl-1 - Google Patents

Formulaciones de un inhibidor de mcl-1

Info

Publication number
AR123327A1
AR123327A1 ARP210102377A ARP210102377A AR123327A1 AR 123327 A1 AR123327 A1 AR 123327A1 AR P210102377 A ARP210102377 A AR P210102377A AR P210102377 A ARP210102377 A AR P210102377A AR 123327 A1 AR123327 A1 AR 123327A1
Authority
AR
Argentina
Prior art keywords
amg
solid dispersion
formulations
mcl
inhibitor
Prior art date
Application number
ARP210102377A
Other languages
English (en)
Inventor
James E Huckle
Markian Stec
Tian Wu
Darren L Reid
Fernando Antonio Alvarez-Nunez
Sean Brown
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR123327A1 publication Critical patent/AR123327A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

En la presente se proporcionan dispersiones sólidas que comprenden AMG 397, métodos para preparar la dispersión sólida y formulaciones farmacéuticas que comprenden AMG 397. Reivindicación 1: Una dispersión sólida que comprende AMG 397 amorfo, o una sal o solvato farmacéuticamente aceptable de este, y un polímero, donde AMG 397 tiene la estructura de fórmula (1). Reivindicación 31: Un método para preparar la dispersión sólida de cualquiera de las reivindicaciones 1 a 18 que comprende mezclar AMG 397 amorfo y el polímero en un disolvente para formar una solución y secar por pulverización la solución para formar la dispersión sólida.
ARP210102377A 2020-08-26 2021-08-23 Formulaciones de un inhibidor de mcl-1 AR123327A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063070630P 2020-08-26 2020-08-26

Publications (1)

Publication Number Publication Date
AR123327A1 true AR123327A1 (es) 2022-11-23

Family

ID=77802255

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102377A AR123327A1 (es) 2020-08-26 2021-08-23 Formulaciones de un inhibidor de mcl-1

Country Status (11)

Country Link
US (1) US20230312606A1 (es)
EP (1) EP4203922A1 (es)
JP (2) JP2022039996A (es)
CN (1) CN116113473A (es)
AR (1) AR123327A1 (es)
AU (1) AU2021330948A1 (es)
CA (1) CA3192624A1 (es)
MX (1) MX2023002352A (es)
TW (1) TW202222321A (es)
UY (1) UY39393A (es)
WO (1) WO2022046690A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物

Also Published As

Publication number Publication date
AU2021330948A1 (en) 2023-03-30
WO2022046690A1 (en) 2022-03-03
JP2022039996A (ja) 2022-03-10
TW202222321A (zh) 2022-06-16
CA3192624A1 (en) 2022-03-03
MX2023002352A (es) 2023-04-14
US20230312606A1 (en) 2023-10-05
JP2023539198A (ja) 2023-09-13
CN116113473A (zh) 2023-05-12
EP4203922A1 (en) 2023-07-05
UY39393A (es) 2022-02-25

Similar Documents

Publication Publication Date Title
ECSP19048759A (es) Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, y proceso para producir el modulador
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
UY38602A (es) Compuestos tricíclicos condensados
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
CU24487B1 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DOP2022000053A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
UY35298A (es) Formulación en dispersión sólida de un compuesto antiviral
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CL2019001993A1 (es) Inhibidores selectivos de jak1.
AR095132A1 (es) Formulación en dispersión sólida de un compuesto antiviral
CR20160438A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
CU20120137A7 (es) Hidrato del hidrocloruro de agomelatina y preparación de éste
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
PE20151051A1 (es) Formulaciones de liberacion modificada para oprozomib
CL2023000655A1 (es) Degradadores de helios basados en pequeñas moléculas de piperidinilo; y uso